{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:31:48Z","timestamp":1740177108400,"version":"3.37.3"},"reference-count":0,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,1,1]],"date-time":"2007-01-01T00:00:00Z","timestamp":1167609600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007155","name":"Medical Research Council Canada","doi-asserted-by":"publisher","award":["PA \u2013 14952"],"award-info":[{"award-number":["PA \u2013 14952"]}],"id":[{"id":"10.13039\/501100007155","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Canadian Journal of Gastroenterology"],"published-print":{"date-parts":[[2007]]},"abstract":"<jats:p>BACKGROUND: Patients with congenital coagulation disorders and chronic hepatitis C virus (HCV) infection have multiple risk factors (ie, infection predominantly with genotype-1 HCV, long duration of the disease, HIV coinfection and male sex) for poor response to antiviral therapy. The present study compared induction therapy with interferon-alpha (IFN-\u03b1)-2b with standard IFN-\u03b12b therapy. Pegylated IFN was not available at the time that the study was initiated.<\/jats:p><jats:p>PATIENTS AND METHODS: A randomized study was performed comparing the efficacy of traditional IFN-\u03b12b therapy (group A \u2013three million units, three times weekly for 24 to 48 weeks) and daily ribavirin (1.0 g to 1.2 g according to weight for 24 to 48 weeks), with induction IFN-\u03b12b therapy (group B \u2013 three million units, daily for eight weeks followed by the same dose administered three times a week for a further 16 to 40 weeks) and daily ribavirin (same dose as above) in IFN-naive patients with congenital coagulation disorders and chronic HCV infection.<\/jats:p><jats:p>RESULTS: Between 2000 and 2003, 54 HIV-negative patients were recruited and randomly assigned to group A or B (n=27 each). Both groups were comparable in terms of age, sex, ethnicity, body mass index, baseline HCV RNA titre, viral genotype, liver fibrosis stage and type of coagulation disorder. Induction therapy did not significantly alter sustained virological response rates (group A 50%, group B 50%; P=1.0). Multiple logistic regression analysis indicated that induction therapy did not benefit individuals with difficult-to-treat infection (ie, those infected with genotypes 1 and 4, or those with high baseline viral loads).<\/jats:p><jats:p>CONCLUSIONS: There was no benefit with induction antiviral therapy for HCV infection in individuals with congenital coagulation disorders.<\/jats:p>","DOI":"10.1155\/2007\/817198","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T04:05:35Z","timestamp":1458014735000},"page":"91-95","source":"Crossref","is-referenced-by-count":0,"title":["Induction Versus Noninduction Antiviral Therapy for Chronic Hepatitis C Virus in Patients with Congenital Coagulation Disorders: A Canadian Multicentre Trial"],"prefix":"10.1155","volume":"21","author":[{"given":"A","family":"Chatterjee","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MG","family":"Swain","sequence":"additional","affiliation":[{"name":"University of Calgary, Calgary, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SS","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Calgary, Calgary, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"VG","family":"Bain","sequence":"additional","affiliation":[{"name":"University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Peltekian","sequence":"additional","affiliation":[{"name":"Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Croitoru","sequence":"additional","affiliation":[{"name":"McMaster University, Hamilton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PC","family":"Adams","sequence":"additional","affiliation":[{"name":"University of Western Ontario, London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Kaita","sequence":"additional","affiliation":[{"name":"University of Manitoba, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Teitel","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EJ","family":"Heathcote","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Toronto, Toronto, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","container-title":["Canadian Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjgh\/2007\/817198.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/cjgh\/2007\/817198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,23]],"date-time":"2016-12-23T19:03:40Z","timestamp":1482519820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/cjgh\/2007\/817198\/abs\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007]]}},"alternative-id":["817198"],"URL":"https:\/\/doi.org\/10.1155\/2007\/817198","relation":{},"ISSN":["0835-7900"],"issn-type":[{"type":"print","value":"0835-7900"}],"subject":[],"published":{"date-parts":[[2007]]}}}